This promotional information is intended for healthcare professionals based
in the UK.
If you are not a healthcare professional in the UK, click here.
For Prescribing and Adverse Event reporting information, click here.
ELIQUIS® (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of venous thromboembolic events (VTE) in patients who have undergone elective hip or knee replacement surgery.
Patient Information Booklet for adult patients on ELIQUIS® for prevention of VTE after elective hip or knee replacement surgery
This booklet is intended only for patients prescribed ELIQUIS (apixaban) for the prevention of VTE after elective hip or knee replacement surgery,1 and should only be read after patients have been prescribed ELIQUIS. This booklet is not intended to replace the Patient Information Leaflet.
This booklet may be read in its electronic form (PDF), or it may be printed and read.
VTE = Venous Thromboembolism